Hiromoto Mizuguchi

Title: Hiromoto Mizuguchi: Innovator in Immunosuppression Research

Introduction

Hiromoto Mizuguchi is a notable inventor based in Frederick, MD (US). He has made significant contributions to the field of immunology, particularly in understanding and treating progressive immunosuppression. His work has implications for immunotherapy and organ transplantation.

Latest Patents

Mizuguchi holds a patent titled "Evaluation and treatment of patients with progressive immunosuppression." This patent describes a soluble immunosuppressive factor present in serum derived from tumor-bearing mammals. It is associated with changes in TCR protein subunit levels and T-lymphocyte signal transduction pathway proteins. The method outlined in the patent provides a way to determine the level of immunosuppression in a mammal by assessing the expression of selected TCR subunit proteins or proteins in the T lymphocyte signal transduction pathway. This innovation is useful for identifying patients with T lymphocytes capable of activation for immunotherapy and for discovering agents that can cause or reverse immunosuppression. Additionally, an isolated immunosuppressive factor linked to the expression levels of these proteins can be utilized to suppress the immune response, particularly in organ transplantation scenarios. Mizuguchi has 1 patent to his name.

Career Highlights

Throughout his career, Mizuguchi has worked with various esteemed organizations. Notably, he has been associated with the United States of America as represented by the Department of Health and Regents of the University of Minnesota. His research has contributed to advancements in immunology and therapeutic strategies.

Collaborations

Mizuguchi has collaborated with prominent figures in the field, including John J O'Shea and Dan L Longo. These collaborations have further enriched his research and innovations.

Conclusion

Hiromoto Mizuguchi's work in immunosuppression research highlights his role as an innovator in the medical field. His patent and collaborations reflect his commitment to advancing healthcare solutions.